

## Larotrectinib, TRK inhibitor (pan)

Catalog	Unit
TBI4832-5MG	5 mg
TBI4832-25MG	25 mg

### Product Details

**Formal Name:** (3S)-N-[5-[(2R)-2-(2,5-Difluorophenyl)pyrrolidine-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide

**Alternate Names:** LOXO-101; ARRY-470

**Molecular Formula:** C<sub>21</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>2</sub>

**Formula Weight:** 428.44

**CAS Number:** 1223403-58-4


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 5 mg/ml)

**Storage:** RT

**Stability:** ≥ 1 year.



### Applications

TRK inhibitor (pan)

### Functions

Potent (IC<sub>50</sub>'s < 11 nM) inhibitor of tropomyosin receptor kinases A, B, and C (TrkA, B, and C). It is >100 fold selective against a panel of 229 kinases. Markedly attenuates bone cancer pain, and significantly blocks formation of neuroma-like structures and the sprouting of sensory nerve fibers. Larotrectinib caused substantial tumor regression in various cancers displaying TRK gene fusions and is the first tissue agnostic cancer drug approved by the FDA.

### Application Procedures

First dissolved in DMSO (up to 5 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20° for up to 2 months.

**For research use only.**